Business Wire

Core42 “Maximus-384” Cluster Secures Top 20 Ranking on the Global TOP500 Supercomputers List

18.11.2025 14:24:00 CET | Business Wire | Press Release

Share

Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced that itsMaximus-384 supercomputer has been ranked No. 20 globally on the TOP500 List, the industry’s most recognized benchmark for publicly known supercomputing systems. The ranking highlights the performance of the AMD Instinct™ MI300X GPU-based “Maximus” cluster, operated at the company’s facility in Buffalo, New York and released ahead of Supercomputing 2025, the leading global conference for HPC.

The TOP500 list tracks performance trends across the global supercomputing systems using the High Performance Linpack benchmark (HPL) benchmark. Securing a top-20 position reflects exceptional engineering across compute, memory, storage, and networking, and validates the cluster’s ability to support large scale AI and HPC workloads under sustained production conditions.

Through G42’s strategic collaboration with AMD, Core42’s Buffalo deployment features more than 9,000+ AMD Instinct MI300X GPUs configured for large-scale AI training and inference. Delivered globally via the Core42 AI Cloud, the cluster provides organizations with access to advanced GPU capacity supported by unified orchestration, strong security controls, and comprehensive data management.

The Core42 AI Cloud infrastructure has been purpose-built as a high-performance computing (HPC) system optimized for AI workloads. Its compute island operates as a self-contained environment with dedicated high-performance storage and a backbone network delivering exceptional speed and reliability. This segmentation supports the ability to deploy multiple types of silicon which is central to the heterogeneous AI Cloud which Core42 has built which also includes Nvidia and Cerebras accelerators. This architecture is powered by Broadcom’s high-bandwidth networking chips, which handle data transfer between GPUs, CPUs, and storage, and Arista Networks’ Ethernet switches and EOS software, which manage traffic flow and optimize data routing.

The Core42 Maximus-384 cluster provides organizations with access to advanced GPU capacity supported by unified orchestration, enterprise-grade security, and comprehensive data-management controls. Its placement on the TOP500 List represents an important milestone for the Core42 AI Cloud and reinforces the company’s ability to operate enterprise-grade, high-performance environments at global scale.

Commenting on the achievement, Edmondo Orlotti, Chief Growth Officer at Core42, said:
“This ranking marks a new milestone in our mission to support the world’s most demanding workloads. Our expanding grid of AI infrastructure spans sovereign clusters and international supercomputing deployments, creating a global backbone built for ultra-low latency and regulatory compliance. Landing in the top 20 globally proves the quality of infrastructure we are building across regions and showcases the strength of our AI Cloud architecture and enterprise-grade capabilities. As AI adoption accelerates, we remain focused on expanding secure, high-performance environments that help organizations and individuals innovate with confidence. From startups to multinationals, we provide the tools to innovate responsibly and at scale.”

TOP500 says that the system has Linpack performance of 114.50 petaflops and a theoretical peak (Rpeak) of 251.15 petaflops.

The Buffalo cluster is operated within TeraWulf’s Lake Mariner facility as part of G42’s strategic partnership with the company. The site provides the power resiliency, cooling efficiency, and operational scale required for large GPU deployments, bringing together Core42’s high-performance AI infrastructure with TeraWulf’s zero-carbon, energy-efficient compute environment. As one of the international regions supporting the Core42 AI Cloud, the Buffalo facility enables scalable AMD Instinct MI300X GPU capacity for advanced training and inference workloads while maintaining the enterprise-grade performance, environmental standards, and reliability applied across every Core42 region.

“Core42’s TOP500 achievement showcases the power of combining AMD Instinct MI300X GPUs with world-class AI infrastructure. Together, we’re advancing scalable, high-performance environments that enable customers to accelerate innovation and unlock the next wave of AI and HPC capabilities," said Negin Oliver, corporate vice president, business development, Data Center GPU Business, AMD.

To learn more, please visit: https://www.core42.ai/

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118733190/en/

Contacts

Andrew Burton
Manager, PR and Communications
E-Mail: communications@core42.ai

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye